JP2010524952A5 - - Google Patents

Download PDF

Info

Publication number
JP2010524952A5
JP2010524952A5 JP2010504191A JP2010504191A JP2010524952A5 JP 2010524952 A5 JP2010524952 A5 JP 2010524952A5 JP 2010504191 A JP2010504191 A JP 2010504191A JP 2010504191 A JP2010504191 A JP 2010504191A JP 2010524952 A5 JP2010524952 A5 JP 2010524952A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010504191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524952A (ja
JP5635398B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/060366 external-priority patent/WO2008128231A1/en
Publication of JP2010524952A publication Critical patent/JP2010524952A/ja
Publication of JP2010524952A5 publication Critical patent/JP2010524952A5/ja
Application granted granted Critical
Publication of JP5635398B2 publication Critical patent/JP5635398B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010504191A 2007-04-16 2008-04-15 ピリミジン誘導体 Expired - Fee Related JP5635398B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91192107P 2007-04-16 2007-04-16
US60/911,921 2007-04-16
PCT/US2008/060366 WO2008128231A1 (en) 2007-04-16 2008-04-15 Pyrimidine derivatives

Publications (3)

Publication Number Publication Date
JP2010524952A JP2010524952A (ja) 2010-07-22
JP2010524952A5 true JP2010524952A5 (enExample) 2011-06-02
JP5635398B2 JP5635398B2 (ja) 2014-12-03

Family

ID=39854302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010504191A Expired - Fee Related JP5635398B2 (ja) 2007-04-16 2008-04-15 ピリミジン誘導体

Country Status (17)

Country Link
US (2) US8349859B2 (enExample)
EP (1) EP2154967B9 (enExample)
JP (1) JP5635398B2 (enExample)
KR (1) KR101424847B1 (enExample)
BR (1) BRPI0809715A2 (enExample)
CA (1) CA2684470C (enExample)
DK (1) DK2154967T5 (enExample)
ES (1) ES2465673T3 (enExample)
HR (1) HRP20140377T2 (enExample)
MX (1) MX2009011199A (enExample)
NZ (1) NZ580671A (enExample)
PL (1) PL2154967T3 (enExample)
PT (1) PT2154967E (enExample)
RU (1) RU2455994C2 (enExample)
SI (1) SI2154967T1 (enExample)
TW (1) TWI484960B (enExample)
WO (1) WO2008128231A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
TWI491605B (zh) * 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
AR074209A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ttk阻害作用を有するピリジンおよびピリミジン誘導体
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
CN102070618B (zh) 2009-11-23 2013-08-21 和记黄埔医药(上海)有限公司 一种化合物及其晶体
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
EP2395001A1 (en) 2010-05-21 2011-12-14 Chemilia AB Novel pyrimidine derivatives
EP2433636A1 (en) * 2010-09-27 2012-03-28 Medizinische Universität Wien Treatment of Malignant Diseases
US8785467B2 (en) 2010-09-30 2014-07-22 Merck Sharp & Dohme Corp. Alkoxy pyrimidine PDE10 inhibitors
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
EP2502924A1 (en) 2011-03-24 2012-09-26 Chemilia AB Novel pyrimidine derivatives
WO2013054351A1 (en) * 2011-08-08 2013-04-18 Cadila Healthcare Limited Heterocyclic compounds
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
AU2013337297A1 (en) 2012-11-05 2015-05-21 Nantbio, Inc. Substituted indol-5-ol derivatives and their therapeutical applications
WO2014145403A1 (en) 2013-03-15 2014-09-18 Nantbio, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
CN105601573B (zh) * 2014-11-24 2021-07-02 中国科学院上海药物研究所 2-氨基嘧啶类化合物及其药物组合物和应用
US10766879B2 (en) * 2015-02-27 2020-09-08 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
WO2017190050A1 (en) 2016-04-28 2017-11-02 Cornell University Inhibitors of soluble adenylyl cyclase
CN112469713B (zh) * 2019-06-21 2023-09-01 江苏豪森药业集团有限公司 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
CN111004221B (zh) * 2019-12-13 2021-02-02 长治学院 一种嘧啶/苯并咪唑杂合物、制备方法及医药用途
CN116528869A (zh) * 2020-11-27 2023-08-01 安锐生物医药科技(广州)有限公司 氨基杂芳基激酶抑制剂

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
DK1553097T3 (da) 1999-02-10 2010-12-13 Astrazeneca Ab Quinazolinderivat som angiogeneseinhibitor og mellemprodukter dertil
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
GB0004890D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2001277621A1 (en) * 2000-08-09 2002-03-04 Astrazeneca Ab Antiangiogenic bicyclic derivatives
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
ATE430742T1 (de) * 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
JPWO2002070477A1 (ja) * 2001-03-01 2004-07-02 小野薬品工業株式会社 2−メチルインドール−4−酢酸、その製造方法およびその合成中間体の製造方法
WO2002102783A1 (en) * 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
EP1515955A4 (en) 2002-06-17 2006-05-03 Smithkline Beecham Corp CHEMICAL PROCESS
HRP20050089B1 (hr) * 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2004020434A1 (ja) * 2002-08-30 2004-03-11 Eisai Co., Ltd. 含窒素芳香環誘導体
US7189712B2 (en) 2002-10-10 2007-03-13 Smithkline Beecham Corporation 1,3-Oxazole compounds for the treatment of cancer
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1678147B1 (en) * 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0321710D0 (en) * 2003-09-16 2003-10-15 Novartis Ag Organic compounds
JP2007505858A (ja) * 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な2,4−ジ(フェニルアミノ)ピリミジン
CA2545711A1 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
US7718697B2 (en) 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
KR100807920B1 (ko) 2003-12-23 2008-02-27 화이자 인코포레이티드 신규한 퀴놀린 유도체
DE102004044556A1 (de) * 2004-09-15 2006-03-30 Bayer Healthcare Ag Behandlung viraler Infektionen durch selektive Zerstörung virusinfizierter Zellen mit Stresskinase-Inhibitoren
WO2006053109A1 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
CA2587590A1 (en) * 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
WO2006071079A1 (en) 2004-12-29 2006-07-06 Hanmi Pharm. Co., Ltd. Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
JP2008540436A (ja) * 2005-05-03 2008-11-20 ライジェル ファーマシューティカルズ, インコーポレイテッド Jakキナーゼインヒビターおよびそれらの使用
EA015890B1 (ru) 2005-06-14 2011-12-30 Тайджен Байотекнолоджи Ко. Лтд. Производные пиримидина
WO2007035309A1 (en) * 2005-09-15 2007-03-29 Merck & Co., Inc. Tyrosine kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2010524952A5 (enExample)
JP2012041349A5 (enExample)
JP2011526913A5 (ja) キナゾリン化合物及び同化合物を含む治療薬
JP2011519956A5 (ja) キナゾリン誘導体及び同キナゾリン誘導体を含む治療薬
JP2013537203A5 (enExample)
JP2015508749A5 (enExample)
HRP20140377T2 (hr) Derivati pirimidina
JP2016503797A5 (enExample)
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
JP2012516871A5 (enExample)
JP2017526677A5 (enExample)
JP2017508782A5 (enExample)
BRPI0820112B8 (pt) derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento
JP2018502912A5 (enExample)
JP2016505614A5 (enExample)
JP2014512364A5 (enExample)
JP2013530176A5 (enExample)
JP2011504903A5 (enExample)
JP2016534134A5 (enExample)
JP2011509949A5 (enExample)
JP2009523760A5 (enExample)
JP2009536620A5 (enExample)
JP2016505637A5 (enExample)
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
JP2017504635A5 (enExample)